Essential

Subscribe today for access to
Articles and Reports

By Tara Cepull, MA | Dec 18, 2024 | 1 min read

Revenue cycle management experts weigh in on the biggest developments of 2024 and how labs can best prepare for 2025 and beyond

Cases filed or resolved by the U.S. Department of Justice in the fourth quarter reveal the same compliance issues from early in 2024

By Michael Schubert, PhD | Dec 18, 2024 | 1 min read

ADLM president Anthony Killeen looks at labs’ staffing struggles in 2024 and what can be done to alleviate them in the coming year

By Ron Shinkman | Jan 30, 2024 | 1 min read

Whether the MiniDraw™ device dredges up memories of Theranos’ failed tech remains to be seen.

By Ron Shinkman | Jan 30, 2024 | 1 min read

More aggressive use of artificial intelligence may mitigate issues that lead to the uneven impact of the disease on this group.

By Rachel Muenz | Jan 26, 2024 | 1 min read

Ann Lambrix, vice president of RCM Solutions at Lighthouse Lab Services, discusses key developments in lab billing and coding.

Recent cases show labs should be wary of issues such as improper relationships, medical necessity, kickbacks, and potential telehealth fraud.

By Michael Schubert, PhD | Jan 23, 2024 | 1 min read

Understanding the 2024 CLFS update—and the changes that are still to come.

By Michael Schubert, PhD | Jan 23, 2024 | 1 min read

What clinical validation really means—and why every member of the laboratory should understand it.

By Tara Cepull, MA | Jan 23, 2024 | 1 min read

Audits can be helpful not just for compliance purposes, but for maximizing reimbursement and maintaining a healthy business.

By Rachel Muenz | Jan 9, 2024 | 1 min read

ASCP chief medical officer Ali Brown, MD, FASCP, discusses the highlights of 2023 and ASCP’s plans for supporting its members in 2024.

By Glenn S. Demby | Jan 9, 2024 | 1 min read

An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.

By Glenn S. Demby | Jan 9, 2024 | 1 min read

G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.